[EN] ROR NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS NUCLÉAIRES ROR
申请人:ABBVIE INC
公开号:WO2016198908A1
公开(公告)日:2016-12-15
The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
[EN] SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS<br/>[FR] PYRIDOPYRAZINES SUBSTITUÉES EN TANT QUE NOUVEAUX INHIBITEURS DE SYK
申请人:HUTCHISON MEDIPHARMA LTD
公开号:WO2012167423A1
公开(公告)日:2012-12-13
Provided are certain pyridopyrazine compounds, pharmaceutical compositions thereof and methods of use therefor.
提供了某些吡啶吡嗪化合物,其药物组成物以及使用方法。
Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
申请人:FUCHINO Kouki
公开号:US20100216726A1
公开(公告)日:2010-08-26
The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.
Substituted pyrido[3,4-b]pyrazines as Syk inhibitors
申请人:Su Wei-Guo
公开号:US09434726B2
公开(公告)日:2016-09-06
Provided are pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.
NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
申请人:AbbVie Inc.
公开号:EP3636643A1
公开(公告)日:2020-04-15
The invention provides compounds of the following formula, pharmaceutically acceptable salts thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.